Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Gaine, Sean"" wg kryterium: Autor


Tytuł :
Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement.
Autorzy :
Price LC; National Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK; National Heart and Lung Institute, Imperial College London, London, UK. Electronic address: .
Martinez G; Department of Anaesthesia and Intensive Care, Royal Papworth Hospital, Cambridge, UK.
Brame A; National Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK; Intensive Care unit and Pulmonary Hypertension Service, London, UK.
Pickworth T; Department of Anaesthesia, Royal Brompton Hospital, London, UK.
Samaranayake C; National Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK.
Alexander D; Department of Anaesthesia, Royal Brompton Hospital, London, UK.
Garfield B; National Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK; Adult Intensive Care Unit, Royal Brompton Hospital, London, UK.
Aw TC; Department of Anaesthesia, Royal Brompton Hospital, London, UK.
McCabe C; National Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK; National Heart and Lung Institute, Imperial College London, London, UK.
Mukherjee B; National Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK; Intensive Care unit and Pulmonary Hypertension Service, London, UK.
Harries C; National Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK.
Kempny A; National Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK; National Heart and Lung Institute, Imperial College London, London, UK.
Gatzoulis M; National Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK; National Heart and Lung Institute, Imperial College London, London, UK.
Marino P; Intensive Care unit and Pulmonary Hypertension Service, London, UK.
Kiely DG; Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
Condliffe R; Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
Howard L; National Pulmonary Hypertension Service, Hammersmith Hospital, London, UK.
Davies R; National Pulmonary Hypertension Service, Hammersmith Hospital, London, UK.
Coghlan G; National Pulmonary Hypertension Service, Royal Free Hospital, London, UK.
Schreiber BE; National Pulmonary Hypertension Service, Royal Free Hospital, London, UK.
Lordan J; National Pulmonary Hypertension Service, Freeman Hospital, Newcastle upon Tyne, UK.
Taboada D; Pulmonary Vascular Disease Unit, Royal Papworth Hospital, Cambridge, UK.
Gaine S; National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland.
Johnson M; Scottish Pulmonary Vascular Unit, NHS Golden Jubilee, Clydebank, UK.
Church C; Scottish Pulmonary Vascular Unit, NHS Golden Jubilee, Clydebank, UK.
Kemp SV; Department of Respiratory Medicine, Royal Brompton Hospital, London, UK.
Wong D; Intensive Care unit and Pulmonary Hypertension Service, London, UK.
Curry A; Cardiothoracic Anaesthesia, University Hospital Southampton, Southampton, Hampshire, UK.
Levett D; Anaesthesia and Critical Care Research Area, Southampton NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Integrative Physiology and Critical Illness Group, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Price S; Adult Intensive Care Unit, Royal Brompton Hospital, London, UK.
Ledot S; Adult Intensive Care Unit, Royal Brompton Hospital, London, UK.
Reed A; National Heart and Lung Institute, Imperial College London, London, UK; Respiratory and Lung Transplantation, Harefield Hospital, Uxbridge, UK.
Dimopoulos K; National Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK; National Heart and Lung Institute, Imperial College London, London, UK.
Wort SJ; National Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK; National Heart and Lung Institute, Imperial College London, London, UK.
Pokaż więcej
Źródło :
British journal of anaesthesia [Br J Anaesth] 2021 Apr; Vol. 126 (4), pp. 774-790. Date of Electronic Publication: 2021 Feb 19.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Consensus*
Expert Testimony/*standards
Hypertension, Pulmonary/*surgery
Perioperative Care/*standards
Postoperative Complications/*prevention & control
Expert Testimony/methods ; Humans ; Hypertension, Pulmonary/diagnosis ; Perioperative Care/methods ; Postoperative Complications/diagnosis
Czasopismo naukowe
Tytuł :
COVID-19 induces a hyperactive phenotype in circulating platelets.
Autorzy :
Comer SP; Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin Ireland.; School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland.
Cullivan S; Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.
Szklanna PB; Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin Ireland.; School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland.
Weiss L; Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin Ireland.; School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland.
Cullen S; School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Kelliher S; Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland.
Smolenski A; School of Medicine, University College Dublin, Dublin, Ireland.
Murphy C; Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin Ireland.; Department of Paediatrics, Royal College of Surgeons in Ireland, Dublin, Ireland.
Altaie H; SAS UK Headquarters, Wittington House, Henley Road, Medmenham, Marlow, Buckinghamshire, United Kingdom.
Curran J; SAS Institute Ltd, Dublin, Ireland.
O'Reilly K; Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.; School of Medicine, University College Dublin, Dublin, Ireland.
Cotter AG; School of Medicine, University College Dublin, Dublin, Ireland.; UCD Centre for Experimental Pathogen and Host Research, Dublin, Ireland.; Department of Infectious Diseases, Mater Misericordiae University Hospital, Dublin, Ireland.
Marsh B; School of Medicine, University College Dublin, Dublin, Ireland.; Department of Critical Care Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.
Gaine S; Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.; School of Medicine, University College Dublin, Dublin, Ireland.
Mallon P; School of Medicine, University College Dublin, Dublin, Ireland.; Department of Infectious Diseases, St Vincent's University Hospital, Dublin, Ireland.
McCullagh B; Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.; School of Medicine, University College Dublin, Dublin, Ireland.
Moran N; School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Ní Áinle F; Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin Ireland.; Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland.; School of Medicine, University College Dublin, Dublin, Ireland.; Department of Haematology, Rotunda Hospital, Dublin, Ireland.
Kevane B; Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin Ireland.; Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland.; School of Medicine, University College Dublin, Dublin, Ireland.
Maguire PB; Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin Ireland.; School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland.; UCD Institute for Discovery, University College Dublin, Dublin, Ireland.
Pokaż więcej
Corporate Authors :
COCOON Study investigators
Źródło :
PLoS biology [PLoS Biol] 2021 Feb 17; Vol. 19 (2), pp. e3001109. Date of Electronic Publication: 2021 Feb 17 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Blood Platelets/*virology
COVID-19/*blood
Adenosine Triphosphate/metabolism ; Aged ; Blood Coagulation ; Blood Platelets/cytology ; Enzyme-Linked Immunosorbent Assay ; Female ; Hemostasis ; Humans ; Inflammation ; Intensive Care Units ; Male ; Mean Platelet Volume ; Middle Aged ; P-Selectin/blood ; Phenotype ; Platelet Factor 4/blood ; Platelet Function Tests ; Thrombopoietin/blood
Czasopismo naukowe
Tytuł :
Relationship Between Time From Diagnosis and Morbidity or Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
Autorzy :
Gaine S; National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland. Electronic address: .
Sitbon O; Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France.
Channick RN; David Geffen School of Medicine at UCLA, Los Angeles, CA.
Chin KM; UT Southwestern Medical Center, Dallas, TX.
Sauter R; Actelion Pharmaceuticals, Ltd., Allschwil, Switzerland.
Galiè N; Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Bologna, Italy.
Hoeper MM; Department of Respiratory Medicine, Hannover Medical School and German Center for Lung Research, Hannover, Germany.
McLaughlin VV; Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Preiss R; Actelion Pharmaceuticals, Ltd., Allschwil, Switzerland.
Rubin LJ; Division of Pulmonary and Critical Care Medicine, University of California, San Diego, CA.
Simonneau G; Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France.
Tapson V; Cedars-Sinai Medical Center, Los Angeles, CA.
Ghofrani HA; University of Giessen and Marburg Lung Center, Giessen, Germany, and member of the German Center for Lung Research, and Department of Medicine, Imperial College London, London, UK.
Lang I; Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Allgemeines Krankenhaus, Vienna, Austria.
Pokaż więcej
Źródło :
Chest [Chest] 2021 Feb 03. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries.
Autorzy :
Cohen AT; Guy's and St Thomas' NHS Foundation Trust, King's College London, UK. Electronic address: .
Hoffmann U; Division of Angiology, Medical Clinic IV, University Hospital, Ludwig-Maximilians-University, Munich, Germany. Electronic address: .
Hainaut P; Department of General Internal Medicine, Cliniques Universitaires Saint Luc, UCL, Bruxelles, Belgium. Electronic address: .
Gaine S; National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland. Electronic address: .
Ay C; Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Electronic address: .
Coppens M; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: .
Schindewolf M; Swiss Cardiovascular Center, Division of Vascular Medicine, University Hospital Bern, Switzerland. Electronic address: .
Jimenez D; Respiratory Department, Ramón y Cajal Hospital, Madrid, Spain. Electronic address: .
Brüggenjürgen B; Institute for Health Economics, Steinbeis-University, Berlin, Germany. Electronic address: .
Levy P; LEDa-LEGOS, Université Paris-Dauphine, PSL University, Paris, France. Electronic address: .
Laeis P; Daiichi Sankyo Europe GmbH, Munich, Germany. Electronic address: .
Fronk EM; Daiichi Sankyo Europe GmbH, Munich, Germany. Electronic address: .
Zierhut W; Daiichi Sankyo Europe GmbH, Munich, Germany. Electronic address: .
Malzer T; Daiichi Sankyo Europe GmbH, Munich, Germany. Electronic address: .
Manu MC; Daiichi Sankyo Europe GmbH, Munich, Germany. Electronic address: .
Reimitz PE; Daiichi Sankyo Europe GmbH, Munich, Germany. Electronic address: .
Bramlage P; Institute for Pharmacology and Preventive Medicine, Berlin, Germany. Electronic address: .
Agnelli G; Internal and Cardiovascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy. Electronic address: .
Pokaż więcej
Corporate Authors :
ETNA-VTE-Europe investigators
Źródło :
European journal of internal medicine [Eur J Intern Med] 2020 Dec; Vol. 82, pp. 48-55. Date of Electronic Publication: 2020 Aug 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Factor Xa Inhibitors*/therapeutic use
Venous Thromboembolism*/drug therapy
Venous Thromboembolism*/epidemiology
Anticoagulants/therapeutic use ; Europe ; Female ; Humans ; Prospective Studies ; Pyridines ; Thiazoles
Czasopismo naukowe
Tytuł :
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.
Autorzy :
Agnelli G; Internal and Cardiovascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy. Electronic address: .
Hoffmann U; Division of Angiology, Medical Clinic IV, University Hospital, Ludwig-Maximilians-University, Munich, Germany. Electronic address: .
Hainaut P; Department of General Internal Medicine, Cliniques Universitaires Saint Luc, UCL, Bruxelles, Belgium. Electronic address: .
Gaine S; National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland. Electronic address: .
Ay C; Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Electronic address: .
Coppens M; Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands. Electronic address: .
Schindewolf M; Division of Angiology, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, University of Bern, Switzerland. Electronic address: .
Jimenez D; Respiratory Department, Ramón y Cajal Hospital, Madrid, Spain.
Brüggenjürgen B; Institute for Health Economics, Steinbeis-University, Berlin, Germany. Electronic address: .
Levy P; LEDa-LEGOS, Université Paris-Dauphine, PSL University, Paris, France. Electronic address: .
Laeis P; Daiichi Sankyo Europe GmbH, Munich, Germany. Electronic address: .
Fronk EM; Daiichi Sankyo Europe GmbH, Munich, Germany. Electronic address: .
Zierhut W; Daiichi Sankyo Europe GmbH, Munich, Germany. Electronic address: .
Malzer T; Daiichi Sankyo Europe GmbH, Munich, Germany. Electronic address: .
Manu MC; Daiichi Sankyo Europe GmbH, Munich, Germany. Electronic address: .
Reimitz PE; Daiichi Sankyo Europe GmbH, Munich, Germany. Electronic address: .
Bramlage P; Institute for Pharmacology and Preventive Medicine, Berlin, Germany. Electronic address: .
Cohen AT; Guy's and St Thomas' NHS Foundation Trust, King's College London, United Kingdom. Electronic address: .
Pokaż więcej
Corporate Authors :
ETNA-VTE-Europe investigators
Źródło :
Thrombosis research [Thromb Res] 2020 Dec; Vol. 196, pp. 297-304. Date of Electronic Publication: 2020 Sep 12.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
Left atrial vegetation after pulmonary vein isolation.
Autorzy :
Gaine S; Cardiology, St James's Hospital, Dublin, Ireland .
Coughlan JJ; Cardiology, University Hospital Limerick, Limerick, Ireland.
Szirt R; Department of Cardiology, St George Hospital, Kogarah, New South Wales, Australia.
Edroos SA; St James's Hospital, Dublin, Ireland.
Pokaż więcej
Źródło :
BMJ case reports [BMJ Case Rep] 2020 Aug 17; Vol. 13 (8). Date of Electronic Publication: 2020 Aug 17.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Heart Atria*
Postoperative Complications*
Atrial Fibrillation/*surgery
Pulmonary Veins/*surgery
Aged ; Cerebral Hemorrhage ; Endocarditis/etiology ; Humans ; Male ; Streptococcal Infections/drug therapy ; Streptococcal Infections/etiology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents.
Autorzy :
McLaughlin VV; Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI. Electronic address: .
Channick R; Department of Medicine, University of California Los Angeles Medical Center, Los Angeles, CA.
De Marco T; Department of Cardiology, University of California, San Francisco, CA.
Farber HW; Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, MA.
Gaine S; The Mater Hospital, Dublin, Ireland.
Galié N; Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Bologna, Italy.
Krasuski RA; Duke University Hospital, Durham, NC.
Preston I; Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, MA.
Souza R; Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.
Coghlan JG; Department of Cardiology, Royal Free Hospital, London, England.
Frantz RP; Department of Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN.
Hemnes A; Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN.
Kim NH; Department of Cardiothoracic Surgery, University of California San Diego Medical Center, San Diego, CA.
Lang IM; Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Allgemeines Krankenhaus, Vienna, Austria.
Langleben D; Center for Pulmonary Vascular Disease, Cardiology Division, Jewish General Hospital and McGill University, Montreal, QC, Canada.
Li M; Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Sitbon O; Université Paris-Saclay, APHP, Hôpital Bicêtre, Service de Pneumologie, Le Kremlin-Bicêtre, France.
Tapson V; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Frost A; Department of Medicine, Institute of Academic Medicine, Houston Methodist Hospital, Houston, TX.
Pokaż więcej
Źródło :
Chest [Chest] 2020 Apr; Vol. 157 (4), pp. 955-965. Date of Electronic Publication: 2019 Nov 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Epoprostenol*/metabolism
Epoprostenol*/pharmacology
Pulmonary Arterial Hypertension*/etiology
Pulmonary Arterial Hypertension*/physiopathology
Pulmonary Arterial Hypertension*/therapy
Antihypertensive Agents/pharmacology ; Consensus ; Critical Pathways/standards ; Humans ; Needs Assessment
Czasopismo naukowe
Tytuł :
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study.
Autorzy :
Sitbon O; Hôpital Universitaire de Bicêtre, Université Paris Sud, Le Kremlin-Bicêtre, France. Electronic address: .
Chin KM; UT Southwestern Medical Center, Dallas, Texas.
Channick RN; University of California, Los Angeles, Los Angeles, California.
Benza RL; Allegheny General Hospital, Pittsburgh, Pennsylvania.
Di Scala L; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
Gaine S; National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland.
Ghofrani HA; University of Giessen and Marburg Lung Center, member of the German Center of Lung Research, Giessen, Germany; Department of Medicine, Imperial College London, London, United Kingdom.
Lang IM; Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Allgemeines Krankenhaus, Vienna, Austria.
McLaughlin VV; Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan.
Preiss R; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
Rubin LJ; Division of Pulmonary and Critical Care Medicine, University of California, San Diego, California.
Simonneau G; Hôpital Universitaire de Bicêtre, Université Paris Sud, Le Kremlin-Bicêtre, France.
Tapson VF; Cedars-Sinai Medical Center, Los Angeles, California.
Galiè N; Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, Bologna, Italy.
Hoeper MM; Department of Respiratory Medicine and German Center of Lung Research, Hannover Medical School, Hannover, Germany.
Pokaż więcej
Źródło :
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation [J Heart Lung Transplant] 2020 Apr; Vol. 39 (4), pp. 300-309. Date of Electronic Publication: 2020 Jan 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype?
Autorzy :
Peacock AJ; Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, UK.
Ling Y; Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, UK.
Johnson MK; Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, UK.
Kiely DG; Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
Condliffe R; Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
Elliot CA; Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
Gibbs JSR; National Heart and Lung Institute, Imperial College London and Hammersmith Hospital, London, UK.
Howard LS; National Heart and Lung Institute, Imperial College London and Hammersmith Hospital, London, UK.
Pepke-Zaba J; Pulmonary Vascular Disease Unit, Papworth Hospital, Cambridge, UK.
Sheares KKK; Pulmonary Vascular Disease Unit, Papworth Hospital, Cambridge, UK.
Corris PA; Northern Pulmonary Vascular Unit, Freeman Hospital, Newcastle, UK.
Fisher AJ; Northern Pulmonary Vascular Unit, Freeman Hospital, Newcastle, UK.
Lordan JL; Northern Pulmonary Vascular Unit, Freeman Hospital, Newcastle, UK.
Gaine S; National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland.
Coghlan JG; Pulmonary Hypertension Unit, Royal Free Hospital, London, UK.
Wort SJ; Royal Brompton Pulmonary Hypertension and Adult Congenital Heart Centre, London, UK.
Gatzoulis MA; Royal Brompton Pulmonary Hypertension and Adult Congenital Heart Centre, London, UK.
Pokaż więcej
Źródło :
Pulmonary circulation [Pulm Circ] 2020 Mar 30; Vol. 10 (1), pp. 2045894020914851. Date of Electronic Publication: 2020 Mar 30 (Print Publication: 2020).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
How the Right Heart Is Measuring Up in Pulmonary Hypertension.
Autorzy :
Gaine S; National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital and University College Dublin, Dublin, Ireland. Electronic address: .
Pokaż więcej
Źródło :
Chest [Chest] 2020 Jan; Vol. 157 (1), pp. 1-2.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Hypertension, Pulmonary*
Lung Diseases, Interstitial*
Angiography ; Heart Ventricles ; Humans ; Tomography, X-Ray Computed
Opinia redakcyjna
Tytuł :
Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
Autorzy :
Chin KM; Division of Internal Medicine, UT Southwestern Medical Center, Dallas, TX (K.M.C.).
Rubin LJ; Division of Pulmonary and Critical Care Medicine, University of California, San Diego (L.J.R.).
Channick R; David Geffen School of Medicine, University of California Los Angeles (R.C.).
Di Scala L; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland (L.D.S., R.P.).
Gaine S; National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland (S.G.).
Galiè N; Department of Experimental, Diagnostic, and Specialty Medicine - DIMES, University of Bologna, Italy (N.G.).
Ghofrani HA; University of Giessen and Marburg Lung Center, Giessen, Germany, member of the German Center of Lung Research, and Department of Medicine, Imperial College London, London, UK (H.-A.G.).
Hoeper MM; Department of Respiratory Medicine, Hannover Medical School and German Center of Lung Research, Hannover (M.M.H.).
Lang IM; Medical University of Vienna, Department of Internal Medicine II, Division of Cardiology, Allgemeines Krankenhaus, Austria (I.M.L.).
McLaughlin VV; Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor (V.V.M.).
Preiss R; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland (L.D.S., R.P.).
Simonneau G; APHP Centre de Référence de l'Hypertension Pulmonaire, Service de Pneumologie et Soins Intensifs, CHU Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France (G.S., O.S.).
Sitbon O; APHP Centre de Référence de l'Hypertension Pulmonaire, Service de Pneumologie et Soins Intensifs, CHU Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France (G.S., O.S.).
Tapson VF; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA (V.F.T.).
Pokaż więcej
Źródło :
Circulation [Circulation] 2019 May 21; Vol. 139 (21), pp. 2440-2450.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Arterial Pressure*/drug effects
Natriuretic Peptide, Brain/*blood
Peptide Fragments/*blood
Pulmonary Arterial Hypertension/*blood
Pulmonary Artery/*physiopathology
Acetamides/therapeutic use ; Adolescent ; Adult ; Aged ; Antihypertensive Agents/therapeutic use ; Biomarkers/blood ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Pulmonary Arterial Hypertension/drug therapy ; Pulmonary Arterial Hypertension/mortality ; Pulmonary Arterial Hypertension/physiopathology ; Pulmonary Artery/drug effects ; Pyrazines/therapeutic use ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
Autorzy :
Beghetti M; Pediatric Cardiology Unit, Centre Universitaire Romand de Cardiologie et Chirurgie Cardiaque Pédiatrique, University of Geneva and Lausanne, Lausanne, Switzerland.
Channick RN; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Chin KM; Division of Internal Medicine, University of Texas Southwestern, Dallas, TX, USA.
Di Scala L; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
Gaine S; National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland.
Ghofrani HA; University of Giessen and Marburg Lung Center, Giessen, Germany, member of the German Center of Lung Research, and Department of Medicine, Imperial College London, London, UK.
Hoeper MM; Department of Respiratory Medicine, Hannover Medical School and German Centre for Lung Research, Hannover, Germany.
Lang IM; Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.
McLaughlin VV; Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
Preiss R; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
Rubin LJ; Department of Medicine, University of California, San Diego, CA, USA.
Simonneau G; APHP, Centre de Référence de l'Hypertension Pulmonaire, Service de Pneumologie et Soins Intensifs, CHU Bicêtre, Université Paris-Sud, Le Kremlin-Bicêtre, Paris, France.
Sitbon O; APHP, Centre de Référence de l'Hypertension Pulmonaire, Service de Pneumologie et Soins Intensifs, CHU Bicêtre, Université Paris-Sud, Le Kremlin-Bicêtre, Paris, France.
Tapson VF; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Galiè N; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University Hospital, Bologna, Italy.
Pokaż więcej
Źródło :
European journal of heart failure [Eur J Heart Fail] 2019 Mar; Vol. 21 (3), pp. 352-359. Date of Electronic Publication: 2019 Jan 11.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Acetamides*/administration & dosage
Acetamides*/adverse effects
Cardiac Surgical Procedures*/adverse effects
Cardiac Surgical Procedures*/methods
Heart Defects, Congenital*/complications
Heart Defects, Congenital*/mortality
Heart Defects, Congenital*/surgery
Hypertension, Pulmonary*/diagnosis
Hypertension, Pulmonary*/drug therapy
Hypertension, Pulmonary*/etiology
Pyrazines*/administration & dosage
Pyrazines*/adverse effects
Adult ; Antihypertensive Agents/administration & dosage ; Antihypertensive Agents/adverse effects ; Disease Progression ; Double-Blind Method ; Drug Monitoring/methods ; Drug Monitoring/statistics & numerical data ; Early Medical Intervention/methods ; Female ; Humans ; Male ; Middle Aged ; Proportional Hazards Models ; Treatment Outcome
Czasopismo naukowe
Tytuł :
ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension.
Autorzy :
Grünig E; Centre for Pulmonary Hypertension, Thoraxclinic at the University Hospital Heidelberg, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.; Both authors contributed equally.
Eichstaedt C; Centre for Pulmonary Hypertension, Thoraxclinic at the University Hospital Heidelberg, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.; Both authors contributed equally.
Barberà JA; Hospital Clinic IDIBAPS, University of Barcelona, Barcelona and Biomedical Research Networking Center on Respiratory Diseases, Madrid, Spain.
Benjamin N; Centre for Pulmonary Hypertension, Thoraxclinic at the University Hospital Heidelberg, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
Blanco I; Hospital Clinic IDIBAPS, University of Barcelona, Barcelona and Biomedical Research Networking Center on Respiratory Diseases, Madrid, Spain.
Bossone E; Dept of Cardiac Surgery, University Hospital Salerno, Salerno, Italy.
Cittadini A; Dept of Cardiac Surgery, University Hospital Salerno, Salerno, Italy.
Coghlan G; Pulmonary Hypertension Unit, Royal Free Hospital, University College London, London, UK.
Corris P; Dept of Respiratory Medicine, Freeman Hospital, University of Newcastle, Newcastle upon Tyne, UK.
D'Alto M; Dept of Cardiology, Second University of Naples - Monaldi Hospital, Naples, Italy.
D'Andrea A; Dept of Cardiology, Second University of Naples - Monaldi Hospital, Naples, Italy.
Delcroix M; Dept of Pneumology, University Hospital Leuven, Leuven, Belgium.
de Man F; Dept of Pulmonology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
Gaine S; Dept of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.
Ghio S; Divisione di Cardiologia, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy.
Gibbs S; Faculty of Medicine, Imperial College London, National Heart and Lung Institute, London, UK.
Gumbiene L; Competence Centre of Pulmonary Hypertension, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.; Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Howard LS; Hammersmith Hospital, Imperial College NHS Trust, London, UK.
Johnson M; Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, UK.
Jurevičienė E; Competence Centre of Pulmonary Hypertension, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.; Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Kiely DG; Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
Kovacs G; Dept of Internal Medicine, Div. Pulmonology, Medical University of Graz, Graz, Austria.; Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.
MacKenzie A; Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, UK.
Marra AM; Dept of Cardiovascular Imaging, IRCCS S.D.N., Naples, Italy.
McCaffrey N; Dept of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.
McCaughey P; Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, UK.
Naeije R; Dept of Cardiology, University Clinic Brussels - Erasme Hospital, Brussels, Belgium.
Olschewski H; Dept of Internal Medicine, Div. Pulmonology, Medical University of Graz, Graz, Austria.; Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.
Pepke-Zaba J; Pulmonary Vascular Disease Unit, Papworth Hospital, Cambridge, UK.
Reis A; Dept of Internal Medicine, Hospital Geral de Santo António, Porto, Portugal.
Santos M; Dept of Internal Medicine, Hospital Geral de Santo António, Porto, Portugal.
Saxer S; Centre for Pulmonary Hypertension, University Hospital Zurich, Zurich, Switzerland.
Tulloh RM; Dept of Congenital Heart Disease, Bristol Royal Hospital for Children, Bristol, UK.
Ulrich S; Centre for Pulmonary Hypertension, University Hospital Zurich, Zurich, Switzerland.
Vonk Noordegraaf A; Dept of Pulmonology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
Peacock AJ; Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, UK.
Pokaż więcej
Źródło :
The European respiratory journal [Eur Respir J] 2019 Feb 28; Vol. 53 (2). Date of Electronic Publication: 2019 Feb 28 (Print Publication: 2019).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Exercise Therapy/*methods
Hypertension, Pulmonary/*rehabilitation
Pulmonary Medicine/*standards
Rehabilitation/*methods
Chronic Disease ; Echocardiography ; Europe/epidemiology ; Evidence-Based Medicine ; Hemodynamics ; Humans ; Hypertension, Pulmonary/psychology ; Interdisciplinary Communication ; Patient Safety ; Quality of Life ; Rehabilitation/standards ; Risk ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Pulmonary hypertension in chronic lung disease and hypoxia.
Autorzy :
Nathan SD; Inova Fairfax Hospital, Falls Church, VA, USA.
Barbera JA; Dept of Pulmonary Medicine, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.; Biomedical Research Networking Center on Respiratory Diseases, Madrid, Spain.
Gaine SP; Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.
Harari S; U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria, Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare, Ospedale San Giuseppe, MultiMedica IRCCS, Milan, Italy.
Martinez FJ; Weill Cornell Medicine, New York, NY, USA.
Olschewski H; Division of Pulmonology, Medizinische Universitat Graz, Graz, Austria.
Olsson KM; Dept of Respiratory Medicine, Hannover Medical School and Member of the German Center for Lung Research (DZL), Hannover, Germany.
Peacock AJ; Scottish Pulmonary Vascular Unit, Regional Lung and Heart Centre, Glasgow, UK.
Pepke-Zaba J; Pulmonary Hypertension Unit, Papworth Hospital, Cambridge, UK.
Provencher S; Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Quebec City, QC, Canada.
Weissmann N; University of Giessen and Marburg Lung Center (UGMLC), Justus-Liebig University Giessen and Member of the German Center for Lung Research (DZL), Giessen, Germany.
Seeger W; University of Giessen and Marburg Lung Center (UGMLC), Justus-Liebig University Giessen and Member of the German Center for Lung Research (DZL), Giessen, Germany.
Pokaż więcej
Źródło :
The European respiratory journal [Eur Respir J] 2019 Jan 24; Vol. 53 (1). Date of Electronic Publication: 2019 Jan 24 (Print Publication: 2019).
Typ publikacji :
Journal Article; Review
MeSH Terms :
Hypertension, Pulmonary/*epidemiology
Hypoxia/*complications
Lung Diseases, Interstitial/*complications
Pulmonary Disease, Chronic Obstructive/*complications
Animals ; Antihypertensive Agents/therapeutic use ; Chronic Disease ; Humans ; Hypertension, Pulmonary/drug therapy ; Lung Diseases, Interstitial/drug therapy ; Lung Diseases, Interstitial/pathology ; Pulmonary Disease, Chronic Obstructive/drug therapy
Czasopismo naukowe
Tytuł :
Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.
Autorzy :
Cohen AT; 1Guy's and St Thomas' NHS Foundation Trust, King's College London, London, UK.
Ay C; 2Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Hainaut P; 3Department of General Internal Medicine, Cliniques Universitaires Saint Luc, UCL, Bruxelles, Belgium.
Décousus H; 4Centre Hospitalier Universitaire de Saint-Etienne, Saint-Priest En Jarez, France.
Hoffmann U; Division of Angiology, Medical Clinic IV, University Hospital, Ludwig-Maximilians-University, Munich, Germany.
Gaine S; 6National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland.
Coppens M; 7Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
da Silva PM; 8Department of Internal Medicine, Arterial Investigation Unit, Hospital de Santa Marta, Lisbon, Portugal.
Jimenez D; 9Respiratory Department, Ramón y Cajal Hospital, Madrid, Spain.
Amann-Vesti B; 10Division of Angiology, University Hospital Zurich, Zurich, Switzerland.
Brüggenjürgen B; 11Institute for Health Economics, Steinbeis-University, Berlin, Germany.
Levy P; 12LEGOS, Université Paris - Dauphine, Paris, France.
Bastida JL; 13University of Castilla-La Mancha, Talavera de la Reina, Toledo Spain.
Vicaut E; 14Department of Medicine, Université Paris Descartes, Paris, France.
Laeis P; 15Daiichi Sankyo Europe GmbH, Munich, Germany.
Fronk EM; 15Daiichi Sankyo Europe GmbH, Munich, Germany.
Zierhut W; 15Daiichi Sankyo Europe GmbH, Munich, Germany.
Malzer T; 15Daiichi Sankyo Europe GmbH, Munich, Germany.
Bramlage P; Institute for Pharmacology and Preventive Medicine, Berlin, Germany.
Agnelli G; 17Internal and Cardiovascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy.
Pokaż więcej
Corporate Authors :
ETNA-VTE-Europe investigators
Źródło :
Thrombosis journal [Thromb J] 2018 May 31; Vol. 16, pp. 18. Date of Electronic Publication: 2018 May 31 (Print Publication: 2018).
Typ publikacji :
Journal Article; Published Erratum
Czasopismo naukowe
Tytuł :
Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.
Autorzy :
Cohen AT; 1Guy's and St Thomas' NHS Foundation Trust, King's College London, London, UK.
Ay C; 2Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Hainaut P; 3Department of General Internal Medicine, Cliniques Universitaires Saint Luc, UCL, Bruxelles, Belgium.
Décousus H; 4Centre Hospitalier Universitaire de Saint-Etienne, Saint-Priest En Jarez, France.
Hoffmann U; Division of Angiology, Medical Clinic IV, University Hospital, Ludwig-Maximilians-University, Munich, Germany.
Gaine S; 6National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland.
Coppens M; 7Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
da Silva PM; 8Department of Internal Medicine, Arterial Investigation Unit, Hospital de Santa Marta, Lisbon, Portugal.
Castro DJ; 9Respiratory Department, Ramón y Cajal Hospital, Madrid, Spain.
Amann-Vesti B; 10Division of Angiology, University Hospital Zurich, Zurich, Switzerland.
Brüggenjürgen B; 11Institute for Health Economics, Steinbeis-University, Berlin, Germany.
Levy P; 12LEGOS, Université Paris - Dauphine, Paris, France.
Bastida JL; 13University of Castilla-La Mancha, Talavera de la Reina, Toledo, Spain.
Vicaut E; 14Department of Medicine, Université Paris Descartes, Paris, France.
Laeis P; 15Daiichi Sankyo Europe GmbH, Munich, Germany.
Fronk EM; 15Daiichi Sankyo Europe GmbH, Munich, Germany.
Zierhut W; 15Daiichi Sankyo Europe GmbH, Munich, Germany.
Malzer T; 15Daiichi Sankyo Europe GmbH, Munich, Germany.
Bramlage P; Institute for Pharmacology and Preventive Medicine, Berlin, Germany.
Agnelli G; 17Internal and Cardiovascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy.
Pokaż więcej
Corporate Authors :
ETNA-VTE-Europe investigators
Źródło :
Thrombosis journal [Thromb J] 2018 May 01; Vol. 16, pp. 9. Date of Electronic Publication: 2018 May 01 (Print Publication: 2018).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2 ) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study.
Autorzy :
Preston IR; Pulmonary, Critical Care, and Sleep Division, Tufts Medical Center, Boston, Massachusetts. Electronic address: .
Channick RN; Pulmonary and Critical Care, Massachusetts General Hospital, Boston, Massachusetts.
Chin K; Pulmonary and Critical Care Division, University of Texas Southwestern Medical Center, Dallas, Texas.
Di Scala L; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
Farber HW; The Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts.
Gaine S; National Pulmonary Hypertension Unit, Mater Misericordiae Hospital, Dublin, Ireland.
Galiè N; Department of Experimental, Diagnostic and Specialty Medicine, Bologna University Hospital, Bologna, Italy.
Ghofrani HA; Department of Internal Medicine, University of Giessen and Marburg Lung Center, Giessen, Germany, member of the German Center of Lung Research, Giessen, Germany; Department of Medicine, Imperial College London, London, United Kingdom.
Hoeper MM; Department of Respiratory Medicine, Hannover Medical School, Hannover, member of the German Center of Lung Research, Giessen, Germany.
Lang IM; Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
McLaughlin VV; Division of Cardiovascular Medicine, University of Michigan Health System, Ann Arbor, Michigan.
Preiss R; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
Simonneau G; Faculté de Médecine, Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France.
Sitbon O; Faculté de Médecine, Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France.
Tapson VF; Center for Pulmonary Vascular Diseases and Venous Thromboembolism, Cedars-Sinai Medical Center, Los Angeles, California.
Rubin LJ; Department of Medicine, University of California, San Diego Medical School, San Diego, California.
Pokaż więcej
Źródło :
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation [J Heart Lung Transplant] 2018 Mar; Vol. 37 (3), pp. 401-408. Date of Electronic Publication: 2017 Oct 02.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Acetamides/*administration & dosage
Antihypertensive Agents/*administration & dosage
Hypertension, Pulmonary/*drug therapy
Pyrazines/*administration & dosage
Receptors, Epoprostenol/*agonists
Withholding Treatment/*statistics & numerical data
Administration, Oral ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Time Factors
Czasopismo naukowe
Tytuł :
Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.
Autorzy :
McLaughlin VV; Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan. Electronic address: .
Hoeper MM; Department of Respiratory Medicine, Hannover Medical School and German Centre for Lung Research, Hannover, Germany.
Channick RN; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Chin KM; University of Texas Southwestern, Dallas, Texas.
Delcroix M; University Hospitals Leuven, Leuven, Belgium.
Gaine S; National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland.
Ghofrani HA; University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany; Department of Medicine, Imperial College London, London, United Kingdom.
Jansa P; Charles University, Prague, Czech Republic.
Lang IM; Medical University of Vienna, Department of Internal Medicine II, Division of Cardiology, Allgemeines Krankenhaus, Vienna, Austria.
Mehta S; Respirology Division, London Health Sciences Centre, Western University, London, Ontario, Canada.
Pulido T; Cardiopulmonary Department, Ignacio Chávez National Heart Institute, Mexico City, Mexico.
Sastry BKS; CARE Hospitals, Hyderabad, India.
Simonneau G; Hôpital de Bicêtre, Paris, France.
Sitbon O; Hôpital de Bicêtre, Paris, France.
Souza R; INCOR Heart Institute, University of São Paulo, São Paulo, Brazil.
Torbicki A; Medical Centre for Postgraduate Education, CMKP European Health Centre, Otwock, Poland.
Tapson VF; Cedars-Sinai Medical Center, Los Angeles, California.
Perchenet L; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
Preiss R; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
Verweij P; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
Rubin LJ; Division of Pulmonary and Critical Care Medicine, University of California, San Diego Medical School, La Jolla, California.
Galiè N; Istituto di Malattie dell'Apparato Cardiovascolare, Università di Bologna, Bologna, Italy.
Pokaż więcej
Źródło :
Journal of the American College of Cardiology [J Am Coll Cardiol] 2018 Feb 20; Vol. 71 (7), pp. 752-763.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Hypertension, Pulmonary/*diagnosis
Hypertension, Pulmonary/*mortality
Adult ; Aged ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Hypertension, Pulmonary/physiopathology ; Male ; Middle Aged ; Morbidity ; Mortality/trends ; Prognosis ; Survival Rate/trends
Czasopismo naukowe
Tytuł :
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.
Autorzy :
Coghlan JG; Cardiology Department, Royal Free Hospital, London, UK.
Channick R; Pulmonary and Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Chin K; University of Texas Southwestern, Dallas, TX, USA.
Di Scala L; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
Galiè N; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University Hospital, Bologna, Italy.
Ghofrani HA; University of Giessen and Marburg Lung Center, Giessen, Germany.; German Center of Lung Research (DZL), Giessen, Germany.; Department of Medicine, Imperial College London, London, UK.
Hoeper MM; Department of Respiratory Medicine, Hannover Medical School and German Centre for Lung Research, Hannover, Germany.
Lang IM; Division of Cardiology, Department of Internal Medicine II, Allgemeines Krankenhaus, Medical University of Vienna, Vienna, Austria.
McLaughlin V; Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
Preiss R; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
Rubin LJ; Department of Medicine, University of California, San Diego, CA, USA.
Simonneau G; Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.; Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Université Paris-Sud, Le Kremlin-Bicêtre, France.; INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France.
Sitbon O; Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.; Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Université Paris-Sud, Le Kremlin-Bicêtre, France.; INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France.
Tapson VF; Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Gaine S; National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Eccles Street, Dublin, Ireland. .
Pokaż więcej
Źródło :
American journal of cardiovascular drugs : drugs, devices, and other interventions [Am J Cardiovasc Drugs] 2018 Feb; Vol. 18 (1), pp. 37-47.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Epoprostenol*
Acetamides/*administration & dosage
Antihypertensive Agents/*administration & dosage
Drug Delivery Systems/*methods
Hypertension, Pulmonary/*drug therapy
Pyrazines/*administration & dosage
Signal Transduction/*drug effects
Acetamides/adverse effects ; Adult ; Aged ; Antihypertensive Agents/adverse effects ; Diarrhea/chemically induced ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Headache/chemically induced ; Humans ; Hypertension, Pulmonary/diagnosis ; Hypertension, Pulmonary/epidemiology ; Male ; Middle Aged ; Pyrazines/adverse effects ; Signal Transduction/physiology
Czasopismo naukowe
Tytuł :
Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension.
Autorzy :
Hernández-Sánchez J; 1 2144 Papworth Trials Unit Collaboration , Papworth Hospital, Cambridge, UK.
Harlow L; 2 2144 Pulmonary Vascular Disease Unit , Papworth Hospital, Cambridge, UK.
Church C; 3 41444 Golden Jubilee Hospital , Glasgow, UK.
Gaine S; 4 8881 Mater Misericordia , Dublin, Ireland.
Knightbridge E; 2 2144 Pulmonary Vascular Disease Unit , Papworth Hospital, Cambridge, UK.
Bunclark K; 2 2144 Pulmonary Vascular Disease Unit , Papworth Hospital, Cambridge, UK.
Gor D; 5 Roche Pharmaceuticals, Welwyn Garden City, UK.
Bedding A; 5 Roche Pharmaceuticals, Welwyn Garden City, UK.
Morrell N; 6 2152 University of Cambridge , Cambridge, UK.
Corris P; 7 5994 University of Newcastle , Newcastle, UK.
Toshner M; 2 2144 Pulmonary Vascular Disease Unit , Papworth Hospital, Cambridge, UK.; 6 2152 University of Cambridge , Cambridge, UK.
Pokaż więcej
Źródło :
Pulmonary circulation [Pulm Circ] 2018 Jan-Mar; Vol. 8 (1), pp. 2045893217735820. Date of Electronic Publication: 2017 Sep 28.
Typ publikacji :
Journal Article
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies